Supervisory Board

The Supervisory Board of Medicalgorithmics S.A. consists of at least five and no more than nine members appointed for a joint three-year term. Principles of its operation are regulated in detail in the Articles of Association.

Composition of the Supervisory Board

Andrzej Gładysz, Chairman of the Supervisory Board

He is one the most experienced managers on insurance market, co-founder of insurance and insurance supervision regulations in Poland, with 30-year-old practice in insurance. Commencing as of 1991, he pursued his professional career from Ministry of Finance and State Office of Insurance Supervision through companies within Commercial Union group (currently Aviva), Prudential to PZU group, largest financial group in Central and Eastern Europe. In the years 1996-1998 he held the position of Director of Control Office in PUNU, in the years 1998-2011 numerous positions in Aviva group (general director, commercial proxy, boards member, supervisory boards member), in the years 2011-2017 deputy director of Prudential branch in Poland and commercial proxy of Prudential Polska, and as of 2017 legal office director, member of steering committees and chairman of supervisory boards of companies in PZU group. Attorney-at-law as of 1997. Starting from 1998 activist of insurance self-government within Polish Insurance Chamber, where he is an active voluntary, without remuneration, besides his duties performed in usual course. Social chairman and member of commissions, teams and working groups of PIU (Legal-Legislative Commission, Brokerage Commision, Good Practices Commision, Bancassurance Team), co-founder of new PIU organization model, code of ethics and good practices of PIU. Active and effective market representant in legislation works in parliament and on government level, among others because of his actions new regulations within the scope of personal data protection in insurance, group insurance and anti-money laundering were developed. Participant and lecturer of numerous conferences and trainings regarding organization and regulation of financial market in Poland and abroad, where he represented Poland and Polish insurance market. Winner of many awards and distinctions in the area of insurance. Decorated with the Bronze Merit Cross of RP.


Michał Wnorowski, Vice-chairman of the Supervisory Board

Corporate governance expert. Member of the Association of Independent Non-Executive Directors. Currently independent member of supervisory boards and member of audit committees of listed companies: PKP Cargo, Alumetal, Medicalgorithmics, Polwax,. Earlier served as a member of supervisory boards and audit committees of: Arteria, Voxel, Develia, Robyg, Enter Air, EMC Instytut Medyczny, Braster,, Elektrobudowa, Armatura Kraków, ARM Property. He has been active on the capital market since 1995. In 2012-2016 Investment Director, managing the PZU Group’s Long-Term Equity Portfolio, where he was responsible for the largest investment projects in the equity area and coordination of investments in this asset class across the PZU Group. Previously, director of the analysis and corporate governance team in the PZU Group, responsible for the analysis and selection of companies for investment portfolios, and then supervision over portfolio companies. He has experience in the fields of investment project management, market analysis, business analysis and valuation, securities portfolio management as well as supervision over M&A projects. He is a graduate of the Warsaw School of Economics and the University of Economics in Krakow.


Anna Sobocka, Member of the Supervisory Board

Graduated from University of Łódź, field of study – foreign trade. Graduated from University of Warsaw – postgraduate studies in psychology of human resources management and from IE Business School (Instituto de Empresa) in Madrid, field of study International Executive MBA. Holds following professional certifications: Polish Certified Public Accountant, FCCA, Certified Internal Auditor (CIA) and Certified Fraud Examiner (CFE). Finance professional who combines strategic and tactical financial expertise of 3+ years as CFO and 5+ years as an entrepreneur with deep understanding of international organisations, operating in several industries gained during 15+ years in financial audit and business advisory.


Sławomir Kościak

Licensed Investment Advisor with license number 303 and holder of the CFA (Chartered Financial Analyst) title. A graduate of the Warsaw School of Economics with a specialization in finance and banking, he also studied at the Aarhus School of Business in Denmark and Universität zu Köln in Germany, and completed the Community of European Management Schools – Master’s in International Management (CEMS MIM) management program. Scholarship recipient of the Educational Enterprise Foundation. He has taught courses for securities brokers (ZMiD) and investment advisors (PERK). He has more than 10 years of experience in asset management. Among others, he worked at the European Investment Fund in Luxembourg and the Morgan Stanley real estate fund in Frankfurt. Between 2009 and 2020, he managed a number of different funds and investment strategies within TFI PZU, both with PZU Group’s own money and entrusted by external clients, stock, mixed and absolute return funds. The investment spectrum included companies from the WSE, as well as those listed on EU and US exchanges. Member of the Investment Committee, AUM of more than PLN 20 billion. Since 2014, in the position of Medical Sector Director, he was responsible for investments in companies in the healthcare sector. Deputy Chairman of the Supervisory Board and Member of the Audit Committee at Mabion SA. Member of the Supervisory Board of Urteste S.A.


Paweł Lewicki, PhD

Paul Lewicki is a cognitive scientist, an entrepreneur, and investor. He was a professor of cognitive psychology at the University of Tulsa from 1984 through 2009, where he established the Nonconscious Information Processing Laboratory, using multiple research grants from the National Science Foundation and National Institutes of Health. He was among the first to publish evidence that the advanced expertise acquired by humans from experience, involves multivariate and highly-interactive patterns in data, which are much more complex than what humans are able to consciously articulate or even transfer/communicate. This approach became popular and quickly adopted by the corporate world as so-called “predictive data mining” – making computers derive from Big Data more complex patterns than humans can understand and then use these patterns to make new predictions. Dr. Lewicki started StatSoft, a company that pioneered commercial applications of data mining. StatSoft rapidly became a large developer of data mining solutions for all industries with offices in 30 countries, and over 1 million accounts, where he was a CEO and the main shareholder. StatSoft was sold to Dell in 2014. As a cognitive scientist, Dr. Lewicki continues to develop artificial intelligence (AI) technologies that make computers smarter. As a businessman, Dr. Lewicki invests in (and helps develop) companies that strive to “make a difference” by using AI to promote the general welfare by accelerating technological progress, especially in the area of medicine, that has been traditionally slower in adopting artificial intelligence.


Dr. Krzysztof Siemionow, MD, PhD

Dr. Kris Siemionow, MD, PhD is a board-certified orthopaedic surgeon and an entrepreneur, who founded and co-founded multiple medical companies, that utilize advanced technology to improve clinical outcomes. Dr. Siemionow completed residency at the Cleveland Clinic Foundation in orthopedic surgery and a spine surgery fellowship at Rush University Medical Center. His PhD focused on the effects of inflammation on nerve cell function. Dr. Siemionow is co-founder of Global Spine Outreach a non-for profit organization whose mission is to “save children with severe spinal deformities”. He co-founded Holo Surgical Inc (acquired), a digital surgery company that developed an artificial intelligence-based surgical guidance system, which is currently in clinical use. He also co-founded Inteneural Networks Inc (acquired), a company that utilizes machine learning to diagnose neurodegenerative disorders. He also co-founded Kardiolytics Inc, a company that utilizes machine learning to perform a virtual coronary stress test. Dr. Siemionow has authored over 100 peer reviewed articles, abstracts, and book chapters pertaining to surgery and basic science research. He holds 50 patents and patent applications, which have been successfully commercialized. Dr. Siemionow is currently board member of Dystrogen Therapeutics, Kardiobot, Dystrogen Gene Therapeutics and Biometryks.


David Cash

David Cash is the co-founder and Managing Partner of Medvest Capital, a venture firm which has invested in early-stage medical technology which improve patient outcomes and decrease the cost of patient care. He specializes in developing early- stage strategy, scaling commercial activities, achieving clinical distinction, and attracting later stage capital. Mr. Cash currently serves as director at Providence Medical Technology, Osteal Therapeutics and BrightSpec. Additionally, he serves as a board observer at FreeSpria and Mercator Medical Systems. Prior to creating Medvest Capital, Mr. Cash founded a development firm specializing in healthcare facilities and ambulatory surgery centers. Early in his career, he worked as a financial analyst at CIBC World Markets’ Investment Banking Division. David earned an MBA from the Darden School of Business at the University of Virginia where he was awarded the Genovese Fellowship. His Bachelor of Arts was received from Colgate University with honors.

Audit Committee

The Audit Committee has been appointed as an advisory body acting collectively within the structure of the Supervisory Board. With the members indicated below the Audit Committee meets the criteria of independence from the Company and other requirements specified in Article 129 of the Act of 11 May 2017 on statutory auditors, audit companies and public supervision (Dz.U. z 2017 r. poz. 1089 [Journal of Laws of 2017, item 1089]).


Michał Wnorowski – Chairman of the Audit Committee

Anna Sobocka – Member of the Audit Committee

Andrzej Gładysz – Member of the Audit Committee

David Cash – Member of the Audit Committee

Remuneration and Nomination Committee


Andrzej Gładysz – Chairman of the Remuneration and Nomination Committee

Sławomir Kościak – Member of the Remuneration and Nomination Committee

David Cash – Member of the Remuneration and Nomination Committee


According to the submitted declarations, the Members of the Supervisory Board do not participate in a competing entity as partners in a civil-law or private partnership or joint-stock company and do not participate in a competing legal entity as members of its corporate body. They are not entered in the Register of Insolvent Debtors kept pursuant to the Act on the National Court Register.

In addition, all Members of the Supervisory Board, in accordance with their declarations, comply toward Medicalgorithmics S.A. with:

  • the independence criteria set out in Art. 129 sec. 3 of the Act of May 11, 2017 on statutory auditors, audit firms and public supervision
  • the independence criteria set out in Annex II to the Recommendation of the European Commission 2005/162 / EC of February 15, 2005 on the role of non-executive or supervisory directors of listed companies and on the committees of the (supervisory) board